Eloxx Pharmaceuticals Inc. (ELOX)’s Financial Results Comparing With Akebia Therapeutics Inc. (NASDAQ:AKBA)

As Biotechnology companies, Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) and Akebia Therapeutics Inc. (NASDAQ:AKBA) are our subject to compare. And more specifically their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eloxx Pharmaceuticals Inc. 7 0.00 21.79M -1.45 0.00
Akebia Therapeutics Inc. 6 0.00 91.41M -2.43 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Eloxx Pharmaceuticals Inc. and Akebia Therapeutics Inc.

Profitability

Table 2 provides the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals Inc. 332,595,588.80% -119.8% -83.7%
Akebia Therapeutics Inc. 1,437,264,150.94% -44.8% -28%

Risk & Volatility

A beta of 1.95 shows that Eloxx Pharmaceuticals Inc. is 95.00% more volatile than Standard & Poor’s 500. Akebia Therapeutics Inc. on the other hand, has 1.77 beta which makes it 77.00% more volatile compared to Standard & Poor’s 500.

Liquidity

The current Quick Ratio of Eloxx Pharmaceuticals Inc. is 6 while its Current Ratio is 6. Meanwhile, Akebia Therapeutics Inc. has a Current Ratio of 1.3 while its Quick Ratio is 0.8. Eloxx Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Akebia Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for Eloxx Pharmaceuticals Inc. and Akebia Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eloxx Pharmaceuticals Inc. 0 0 0 0.00
Akebia Therapeutics Inc. 0 0 2 3.00

Competitively Akebia Therapeutics Inc. has an average price target of $16, with potential upside of 113.90%.

Institutional & Insider Ownership

The shares of both Eloxx Pharmaceuticals Inc. and Akebia Therapeutics Inc. are owned by institutional investors at 54.5% and 72.9% respectively. Insiders held roughly 0.4% of Eloxx Pharmaceuticals Inc.’s shares. Competitively, 1% are Akebia Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eloxx Pharmaceuticals Inc. -1.72% -0.19% -18.83% -47.38% -61.17% -57.29%
Akebia Therapeutics Inc. -6.04% 57.18% 38.08% 37.44% -30.72% 6.87%

For the past year Eloxx Pharmaceuticals Inc. had bearish trend while Akebia Therapeutics Inc. had bullish trend.

Summary

On 7 of the 10 factors Akebia Therapeutics Inc. beats Eloxx Pharmaceuticals Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.